Selective optimization of side activities (SOSA) offers an alternative entry to early drug discovery and may provide rapid access to bioactive new chemical entities with desirable properties. SOSA aims to reverse a drug's side activities through structural modification and to design out the drug's original main action. We identified a moderate side activity for the cysteinyl leukotriene receptor 1 (CysLT₁R) antagonist pranlukast on the farnesoid X receptor (FXR). Systematic structural modification of the drug allowed remarkable optimization of its partial FXR agonism to sub‐nanonmolar potency. The resulting FXR modulators lack any activity on CysLT₁R and are characterized by high selectivity, high metabolic stability, and low toxicity. With their favorable in vitro profile, these SOSA‐derived FXR modulators constitute a new FXR ligand chemotype that appears suitable for further preclinical evaluation.

中文翻译：

---

普仑司特对法尼醇X受体调节剂的选择性优化

选择性的副反应优化（SOSA）为早期药物发现提供了另一种选择，并且可以快速获取具有所需特性的具有生物活性的新化学实体。SOSA旨在通过结构修改来扭转药物的副反应，并设计出药物的原始主要作用。我们确定了半胱氨酸白三烯受体1（CysLT ₁ R）拮抗剂普仑司特对法呢类X受体（FXR）的中等副作用。该药物的系统结构修饰使其部分FXR激动剂显着优化至亚纳摩尔浓度。所得的FXR调节剂对CysLT ₁没有任何活性R 1和R 2具有高选择性，高代谢稳定性和低毒性的特征。这些SOSA衍生的FXR调节剂具有良好的体外特性，构成了一种新的FXR配体化学型，似乎适用于进一步的临床前评估。